Nipocalimab (IMAAVY) FcRn receptor blockade for warm autoimmune hemolytic anemia — the monoclonal antibody preventing immunoglobulin G recycling to rapidly reduce pathogenic autoantibody levels without broad immunosuppression — represents the fastest-advancing targeted therapy in the global autoimmune hemolytic anemia landscape, with the Acquired Autoimmune Hemolytic Anemia Market...